Fintel reports that on March 4, 2025, Needham downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy to ...
Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...